UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages

UroGen Pharma Ltd. (NASDAQ:URGN) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $40.00.

Several research firms recently commented on URGN. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Tuesday, February 18th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $64.00 price target on shares of UroGen Pharma in a research report on Tuesday.

UroGen Pharma Trading Down 2.4 %

Shares of URGN stock opened at $9.51 on Wednesday. The stock has a market capitalization of $223.05 million, a price-to-earnings ratio of -3.02 and a beta of 1.08. UroGen Pharma has a 12-month low of $9.29 and a 12-month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock’s 50-day moving average price is $10.64 and its 200-day moving average price is $12.05.

Insider Buying and Selling at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $59,000. Lazard Asset Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $67,000. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $101,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after purchasing an additional 3,856 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.